6 Referenzen

1. Rösen P. Endotheliale Dysfunktion: ein Synonym für funktionelle Atherosklerose. J Kardiol 2002; 9: p. 556-62.
2. Pober JS, and R.C. Cotran. Cytokines and endothelial cell biology. Physiol. Rev. 70: 427-451 1990.
3. Gimbrone MJ, Nagel, T, Topper JN. Biomechanical Activation: an Emerging Paradigm in Endothelial Adhesion Biology. J. Clin. Invest. 1997; 99(8): p. 1809-1813.
4. Triggle CR, Hollenberg M, Anderson TJ, et al. The endothelium in health and disease--a target for therapeutic intervention. J Smooth Muscle Res 2003; 39(6): p. 249-67.
5. Lusis AJ. Atherosclerosis. Nature 2000; 407(6801): p. 233-41.
6. Furchgott RF,Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789): p. 373-6.
7. Koshland DE, Jr. The molecule of the year. Science 1992; 258(5090): p. 1861.
8. Landmesser U, Hornig B,Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109(21 Suppl 1): p. II27-33.
9. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65(1): p. 1-21.
10. Azuma H, Ishikawa M,Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88(2): p. 411-5.
11. Freedman JE, Sauter R, Battinelli EM, et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 1999; 84(12): p. 1416-21.
12. Kubes P, Suzuki M,Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991; 88(11): p. 4651-5.
13. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): p. 868-74.
14. Li H,Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190(3): p. 244-54.
15. Shen YH, Wang XL,Wilcken DE. Nitric oxide induces and inhibits apoptosis through different pathways. FEBS Lett 1998; 433(1-2): p. 125-31.
16. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 1994; 78(6): p. 931-6.
17. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993; 268(17): p. 12231-4.
18. Marletta MA. Nitric oxide synthase: function and mechanism. Adv Exp Med Biol 1993; 338: p. 281-4.
19. Schmidt HH, Lohmann SM,Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993; 1178(2): p. 153-75.
20. Löffler G, *Basiswissen Biochemie mit Pathobiochemie*. Vol. 4. Auflage. 2001, Berlin, Heidelberg, New York: Springer. 262-264.
21. Cendan JC, Souba WW, Copeland EM, 3rd,Lind DS. Cytokines regulate endotoxin stimulation of endothelial cell arginine transport. Surgery 1995; 117(2): p. 213-9.
22. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100(9): p. 2153-7.

23. Bogle RG, Baydoun AR, Pearson JD,Mann GE. Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. J Physiol 1996; 490 (Pt 1): p. 229-41.
24. Hecker M, Sessa WC, Harris HJ, Anggard EE,Vane JR. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A 1990; 87(21): p. 8612-6.
25. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci 1997; 811: p. 60-7; discussion 67-9.
26. Palmer RM, Ashton DS,Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333(6174): p. 664-6.
27. Bredt DS,Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994; 63: p. 175-95.
28. Walford G,Loscalzo J. Nitric oxide in vascular biology. J Thromb Haemost 2003; 1(10): p. 2112-8.
29. Luzzi SD,Marletta MA. L-arginine analogs as alternate substrates for nitric oxide synthase. Bioorg Med Chem Lett 2005; 15(17): p. 3934-41.
30. Vallance P,Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337(8744): p. 776-8.
31. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18(5): p. 1139-43.
32. Fleming I, Bauersachs J, Fisslthaler B,Busse R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res 1998; 82(6): p. 686-95.
33. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R,Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399(6736): p. 601-5.
34. Liu J, Garcia-Cardena G,Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 1996; 35(41): p. 13277-81.
35. Fleming I,Busse R. NO: the primary EDRF. J Mol Cell Cardiol 1999; 31(1): p. 5-14.
36. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA,Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90(3): p. 1168-72.
37. Adams MR, Forsyth CJ, Jessup W, Robinson J,Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 1995; 26(4): p. 1054-61.
38. Adams MR, Jessup W,Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997; 29(3): p. 491-7.
39. Drexler H, Zeiher AM, Meinzer K,Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338(8782-8783): p. 1546-50.
40. Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA,Cannon RO, 3rd. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol 1997; 30(5): p. 1220-7.

41. Chauhan A, More RS, Mullins PA, Taylor G, Petch C,Schofield PM. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol 1996; 28(7): p. 1796-804.
42. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K,Frolich JC. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32(5): p. 1336-44.
43. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29(3): p. 479-85.
44. Leiper J,Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43(3): p. 542-8.
45. Feron O,Kelly RA. The caveolar paradox: suppressing, inducing, and terminating eNOS signaling. Circ Res 2001; 88(2): p. 129-31.
46. Gimbrone A, Topper, JN. Biology of the vessel wall: endothelium. Chien KR (ed.). Molecular Basis of Cardiovascular Disease 1999: p. 331-48.
47. Pinkney JH, Stehouwer CD, Coppack SW,Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46 Suppl 2: p. S9-13.
48. Ross R, Glomset J,Harker L. Response to injury and atherogenesis. Am J Pathol 1977; 86(3): p. 675-84.
49. Cayatte AJ, Palacino JJ, Horten K,Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14(5): p. 753-9.
50. Chen J, Kuhlencordt PJ, Astern J, Gyurko R,Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 2001; 104(20): p. 2391-4.
51. Kuhlencordt PJ, Gyurko R, Han F, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104(4): p. 448-54.
52. Pinkney JH, Downs L, Hopton M, Mackness MI,Bolton CH. Endothelial dysfunction in Type 1 diabetes mellitus: relationship with LDL oxidation and the effects of vitamin E. Diabet Med 1999; 16(12): p. 993-9.
53. Ross R,Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976; 295(7): p. 369-77.
54. Ross R,Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976; 295(8): p. 420-5.
55. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: p. 791-804.
56. Simionescu N, Vasile E, Lupu F, Popescu G,Simionescu M. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol 1986; 123(1): p. 109-25.
57. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation 1991; 84(3): p. 1420-5.
58. Goldstein JL, Ho YK, Basu SK,Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979; 76(1): p. 333-7.
59. Zeiher AM, Fisslthaler B, Schray-Utz B,Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995; 76(6): p. 980-6.

60. Tomita H, Egashira K, Kubo-Inoue M, et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998; 18(9): p. 1456-64.
61. Libby P, Friedman GB,Salomon RN. Cytokines as modulators of cell proliferation in fibrotic diseases. Am Rev Respir Dis 1989; 140(4): p. 1114-7.
62. Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK,Dinarello CA. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 1986; 124(2): p. 179-85.
63. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): p. 115-26.
64. Tsao PS, Buitrago R, Chan JR,Cooke JP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996; 94(7): p. 1682-9.
65. Lefer DJ, Jones SP, Girod WG, et al. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol 1999; 276(6 Pt 2): p. H1943-50.
66. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67(6): p. 1033-6.
67. Luscinskas FW,Gimbrone MA, Jr. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 1996; 47: p. 413-21.
68. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO,Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998; 102(1): p. 145-52.
69. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L,Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000; 191(1): p. 189-94.
70. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001; 88(7B): p. 3J-6J.
71. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104(3): p. 365-72.
72. Libby P,Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103(13): p. 1718-20.
73. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996; 7(5): p. 330-5.
74. Cai H,Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87(10): p. 840-4.
75. Landmesser U,Harrison DG. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 2001; 104(22): p. 2638-40.
76. Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H,Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000; 101(19): p. 2264-70.
77. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 1996; 16: p. 33-50.
78. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ,Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17(3): p. 189-212.

79. Halliwell B. Antioxidant characterization. Methodology and mechanism. Biochem Pharmacol 1995; 49(10): p. 1341-8.
80. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G,Harrison DG. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 2000; 105(11): p. 1631-9.
81. Southorn PA,Powis G. Free radicals in medicine. II. Involvement in human disease. Mayo Clin Proc 1988; 63(4): p. 390-408.
82. Southorn PA,Powis G. Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clin Proc 1988; 63(4): p. 381-9.
83. Halliwell B, Gutteridge JM,Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992; 119(6): p. 598-620.
84. Beckman KB,Ames BN. Mitochondrial aging: open questions. Ann N Y Acad Sci 1998; 854: p. 118-27.
85. Halliwell B,Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984; 219(1): p. 1-14.
86. Kowaltowski AJ,Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26(3-4): p. 463-71.
87. Thomson AM, Rogers JT,Leedman PJ. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol 1999; 31(10): p. 1139-52.
88. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20(9): p. 2032-7.
89. Griendling KK, Sorescu D,Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86(5): p. 494-501.
90. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003; 107(10): p. 1383-9.
91. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111(8): p. 1201-9.
92. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A,Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000; 102(18): p. 2172-9.
93. Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B,Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol 2002; 22(10): p. 1655-61.
94. d'Uscio LV, Milstien S, Richardson D, Smith L,Katusic ZS. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003; 92(1): p. 88-95.
95. Fuster V, Badimon L, Badimon JJ,Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326(4): p. 242-50.
96. Fuster V, Badimon L, Badimon JJ,Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326(5): p. 310-8.
97. Davies MJ,Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310(18): p. 1137-40.
98. MLP DR, *Innere Medizin -Sonderausgabe*. 2001: Springer Verlag. 932-959.

99. Zimmet P, Alberti KG,Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): p. 782-7.
100. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24(4): p. 683-9.
101. Herold G, *Innere Medizin, eine vorlesungsorientierte Darstellung*. 2004. p. 595-619.
102. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20(4): p. 537-44.
103. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): p. 1343-50.
104. King H, Aubert RE,Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): p. 1414-31.
105. Hauner H, Koster I,von Ferber L. [Prevalence of diabetes mellitus in Germany 1998-2001. Secondary data analysis of a health insurance sample of the AOK in Hesse/KV in Hesse]. Dtsch Med Wochenschr 2003; 128(50): p. 2632-7.
106. Kannel WB,McGee DL. Diabetes and cardiovascular disease. The Framingham study. Jama 1979; 241(19): p. 2035-8.
107. Kannel WB,McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2(2): p. 120-6.
108. Hayat SA, Patel B, Khattar RS,Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107(6): p. 539-57.
109. Cosentino F,Luscher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998; 32 Suppl 3: p. S54-61.
110. Giugliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95(7): p. 1783-90.
111. Angulo J, Rodriguez-Manas L, Peiro C, Neira M, Marin J,Sanchez-Ferrer CF. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 1998; 358(5): p. 529-37.
112. Pieper GM, Adams MB,Roza AM. Pancreatic transplantation reverses endothelial dysfunction in experimental diabetes mellitus. Surgery 1998; 123(1): p. 89-95.
113. Koltai MZ, Hadhazy P, Posa I, et al. Characteristics of coronary endothelial dysfunction in experimental diabetes. Cardiovasc Res 1997; 34(1): p. 157-63.
114. Palmer AM, Gopaul N, Dhir S, Thomas CR, Poston L,Tribe RM. Endothelial dysfunction in streptozotocin-diabetic rats is not reversed by dietary probucol or simvastatin supplementation. Diabetologia 1998; 41(2): p. 157-64.
115. Pieper GM, Langenstroer P,Siebeneich W. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res 1997; 34(1): p. 145-56.
116. Rosen P, Du X,Tschope D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Mol Cell Biochem 1998; 188(1-2): p. 103-11.

117. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28(3): p. 573-9.
118. Gazis A, White DJ, Page SR,Cockcroft JR. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet Med 1999; 16(4): p. 304-11.
119. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E,Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993; 42(7): p. 1017-25.
120. Yu HI, Sheu WH, Lai CJ, Lee WJ,Chen YT. Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease. Int J Cardiol 2001; 78(1): p. 19-25.
121. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865): p. 813-20.
122. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C,Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108(9): p. 1341-8.
123. Bierhaus A, Hofmann MA, Ziegler R,Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37(3): p. 586-600.
124. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL,Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14(10): p. 1521-8.
125. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404(6779): p. 787-90.
126. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88(2): p. E14-22.
127. Milstien S,Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999; 263(3): p. 681-4.
128. Forstermann U,Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113(13): p. 1708-14.
129. Komers R, Schutzer WE, Reed JF, et al. Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes 2006; 55(6): p. 1651-9.
130. Srinivasan S, Hatley ME, Bolick DT, et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004; 47(10): p. 1727-34.
131. Ho FM, Liu SH, Liau CS, Huang PJ, Shiah SG,Lin-Shiau SY. Nitric oxide prevents apoptosis of human endothelial cells from high glucose exposure during early stage. J Cell Biochem 1999; 75(2): p. 258-63.
132. Salt IP, Morrow VA, Brandie FM, Connell JM,Petrie JR. High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser1177 phosphorylation in human aortic endothelial cells. J Biol Chem 2003; 278(21): p. 18791-7.

133. Cosentino F, Hishikawa K, Katusic ZS,Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96(1): p. 25-8.
134. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997; 30(2): p. 325-33.
135. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci U S A 2006; 103(39): p. 14537-41.
136. Herr RR,Reusser F. New antibacterial agent (U-24,544) isolated from Streptomyces griseus. Appl Microbiol 1967; 15(5): p. 1142-4.
137. Junod A, Lambert AE, Orci L, Pictet R, Gonet AE,Renold AE. Studies of the diabetogenic action of streptozotocin. Proc Soc Exp Biol Med 1967; 126(1): p. 201-5.
138. Konrad RJ, Mikolaenko I, Tolar JF, Liu K,Kudlow JE. The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic beta-cell O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase. Biochem J 2001; 356(Pt 1): p. 31-41.
139. Arison RN,Feudale EL. Induction of renal tumour by streptozotocin in rats. Nature 1967; 214(94): p. 1254-5.
140. Giorgino F, Chen JH,Smith RJ. Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose. Endocrinology 1992; 130(3): p. 1433-44.
141. Van Voorhis K, Said HM, Abumrad N,Ghishan FK. Effect of chemically induced diabetes mellitus on glutamine transport in rat intestine. Gastroenterology 1990; 98(4): p. 862-6.
142. Rakieten N, Rakieten ML,Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963; 29: p. 91-8.
143. Riva E, Andreoni G, Bianchi R, et al. Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol Res 1998; 37(3): p. 233-40.
144. Tomlinson KC, Gardiner SM,Bennett T. Diabetes mellitus in Brattleboro rats: cardiovascular, fluid, and electrolyte status. Am J Physiol 1989; 256(6 Pt 2): p. R1279-85.
145. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B,Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 1(8636): p. 461-3.
146. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ,den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340(8815): p. 319-23.
147. Dorenkamp M, Riad A, Stiehl S, et al. Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism. Eur J Pharmacol 2005; 520(1-3): p. 179-87.
148. DePaola N, Gimbrone MA, Jr., Davies PF,Dewey CF, Jr. Vascular endothelium responds to fluid shear stress gradients. Arterioscler Thromb 1992; 12(11): p. 1254-7.
149. Lerman-Garber I,Rull Rodrigo JA. Epidemiology of diabetes in Mexico and associated coronary risk factors. Isr Med Assoc J 2001; 3(5): p. 369-73.

150. Alexander CM, Landsman PB,Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 2000; 86(9): p. 897-902.
151. Marks JB,Raskin P. Cardiovascular risk in diabetes: a brief review. J Diabetes Complications 2000; 14(2): p. 108-15.
152. Sowers JR,Lester MA. Diabetes and cardiovascular disease. Diabetes Care 1999; 22 Suppl 3: p. C14-20.
153. Stamler J, Vaccaro O, Neaton JD,Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16(2): p. 434-44.
154. Butler WJ, Ostrander LD, Jr., Carman WJ,Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985; 121(4): p. 541-7.
155. Pan WH, Cedres LB, Liu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986; 123(3): p. 504-16.
156. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH,Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128(2): p. 389-401.
157. Haffner SM, Lehto S, Ronnemaa T, Pyorala K,Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): p. 229-34.
158. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH,Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130(5): p. 963-74.
159. Ding Y, Vaziri ND, Coulson R, Kamanna VS,Roh DD. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab 2000; 279(1): p. E11-7.
160. Guo X, Chen LW, Liu WL,Guo ZG. High glucose inhibits expression of inducible and constitutive nitric oxide synthase in bovine aortic endothelial cells. Acta Pharmacol Sin 2000; 21(4): p. 325-8.
161. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G,Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97(11): p. 2601-10.
162. Makimattila S, Virkamaki A, Groop PH, et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 1996; 94(6): p. 1276-82.
163. Pflueger AC, Osswald H,Knox FG. Adenosine-induced renal vasoconstriction in diabetes mellitus rats: role of nitric oxide. Am J Physiol 1999; 276(3 Pt 2): p. F340-6.
164. Dai FX, Diederich A, Skopec J,Diederich D. Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol 1993; 4(6): p. 1327-36.
165. Hennersdorf MG, Kelm M, Schannwell CM, Rosen P,Strauer BE. [Cardiac complications in diabetes mellitus]. Med Klin (Munich) 2000; 95(9): p. 487-95.
166. Hornig B, Kohler C,Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95(5): p. 1115-8.
167. Haynes WG,Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344(8926): p. 852-4.

168. Taylor SG,Weston AH. Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 1988; 9(8): p. 272-4.
169. Kessler P, Popp R, Busse R,Schini-Kerth VB. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 1999; 99(14): p. 1878-84.
170. Goode GK, Miller JP,Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345(8946): p. 362-4.
171. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993; 91(1): p. 29-37.
172. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81(2): p. 491-7.
173. Reddy KG, Nair RN, Sheehan HM,Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23(4): p. 833-43.
174. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87(1): p. 86-93.
175. Zeiher AM, Drexler H, Wollschlager H,Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83(2): p. 391-401.
176. Hasdai D, Gibbons RJ, Holmes DR, Jr., Higano ST,Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 1997; 96(10): p. 3390-5.
177. Britten MB, Zeiher AM,Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245(4): p. 315-27.
178. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr.,Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101(9): p. 948-54.
179. Heitzer T, Schlinzig T, Krohn K, Meinertz T,Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104(22): p. 2673-8.
180. Ozaki Y, Keane D,Serruys PW. Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina. Circulation 1995; 92(9): p. 2446-56.
181. Zeiher AM, Krause T, Schachinger V, Minners J,Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995; 91(9): p. 2345-52.
182. Widlansky ME, Gokce N, Keaney JF, Jr.,Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42(7): p. 1149-60.
183. Vita JA,Keaney JF, Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106(6): p. 640-2.
184. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996; 28(5): p. 419-26.

185. Feener EP,King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350 Suppl 1: p. SI9-13.
186. Golovchenko I, Goalstone ML, Watson P, Brownlee M,Draznin B. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 87(9): p. 746-52.
187. Schmidt AM,Stern DM. Hyperinsulinemia and vascular dysfunction: the role of nuclear factor-kappaB, yet again. Circ Res 2000; 87(9): p. 722-4.
188. Thurberg BL,Collins T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 1998; 9(5): p. 387-96.
189. Karin M,Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000; 12(1): p. 85-98.
190. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50(12): p. 2792-808.
191. Baeuerle PA. Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 1998; 8(1): p. R19-22.
192. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998; 95(6): p. 729-31.
193. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242(2): p. 237-9.
194. Cha-Molstad H, Agrawal A, Zhang D, Samols D,Kushner I. The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 2000; 165(8): p. 4592-7.
195. Bermudez EA, Rifai N, Buring J, Manson JE,Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22(10): p. 1668-73.
196. Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003; 163(1): p. 93-9.
197. Mojiminiyi OA, Abdella N, Moussa MA, Akanji AO, Al Mohammedi H,Zaki M. Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 58(1): p. 37-44.
198. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5(5): p. 551-9.
199. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106(16): p. 2067-72.
200. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003; 52(3): p. 621-33.
201. Collins T,Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107(3): p. 255-64.
202. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D,Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. Faseb J 1995; 9(10): p. 899-909.

203. Libby P,Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs 1998; 56 Suppl 1: p. 9-13; discussion 33.
204. Baeuerle PA,Baltimore D. NF-kappa B: ten years after. Cell 1996; 87(1): p. 13-20.
205. Bierhaus A, Chen J, Liliensiek B,Nawroth PP. LPS and cytokine-activated endothelium. Semin Thromb Hemost 2000; 26(5): p. 571-87.
206. Cavallo-Perin P, Lupia E, Gruden G, et al. Increased blood levels of platelet-activating factor in insulin-dependent diabetic patients with microalbuminuria. Nephrol Dial Transplant 2000; 15(7): p. 994-9.
207. Gimbrone MA, Jr., Bevilacqua MP,Cybulsky MI. Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann N Y Acad Sci 1990; 598: p. 77-85.
208. Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 1998; 101(9): p. 1905-15.
209. Elhadd TA, Kennedy G, Hill A, et al. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev 1999; 15(6): p. 405-11.
210. Dosquet C, Weill D,Wautier JL. Molecular mechanism of blood monocyte adhesion to vascular endothelial cells. Nouv Rev Fr Hematol 1992; 34 Suppl: p. S55-9.
211. Kado S, Wakatsuki T, Yamamoto M,Nagata N. Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. Life Sci 2001; 68(7): p. 727-37.
212. Fasching P, Waldhausl W,Wagner OF. Elevated circulating adhesion molecules in NIDDM--potential mediators in diabetic macroangiopathy. Diabetologia 1996; 39(10): p. 1242-4.
213. Fasching P, Veitl M, Rohac M, et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81(12): p. 4313-7.
214. Steiner M, Reinhardt KM, Krammer B, Ernst B,Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994; 72(6): p. 979-84.
215. Taddei S, Virdis A, Ghiadoni L, Sudano I,Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62(2): p. 265-84.
216. Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K,Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 2000; 140(5): p. 753-9.
217. Goto K, Fujii K, Onaka U, Abe I,Fujishima M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000; 36(4): p. 575-80.
218. O'Driscoll G, Green D,Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95(5): p. 1126-31.